Rituximab Not Noninferior to Ocrelizumab for Relapsing-Remitting MS
Cumulative hazard of relapses higher among patients treated with rituximab versus ocrelizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.